Cassava, Biogen lead Alzheimer's stocks higher following Roche's gantenerumab setback

Nov. 14, 2022 11:59 AM ETEli Lilly and Company (LLY), BIIB, SAVA, RHHBYESALY, AVXL, ESALF, ANVS, PRTABy: Jonathan Block, SA News Editor37 Comments

Amyloid plaques in Alzheimer"s disease

Artur Plawgo/iStock via Getty Images

  • Several pharma and biotech companies working on Alzheimer's disease treatments are up in Monday trading -- notably Cassava Sciences (NASDAQ:SAVA) and Biogen (NASDAQ:BIIB) -- after Roche (OTCQX:RHHBY) reported its

Recommended For You

Comments (37)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.